Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paulette Anderson

Psychiatry Chestertown, MD Medical Doctor

NPI 1205020161 CMS profile 8423

300 Scheeler Rd, Upper Shore Community Mental Health Center, Chestertown, MD 21620

Open in the dashboard

General payments

$2,569

138 records reported · program years 2019–2025

Research payments

$38

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paulette Anderson of Chestertown, MD is reported in the CMS Open Payments database as having received $2,569 across 138 general payments and $38 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $310 14
2024 General $484 28
2023 General $359 18
2023 Research $38 1
2022 General $431 23
2021 General $469 24
2020 General $263 16
2019 General $253 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paulette Anderson
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Paulette Anderson were reported at $310. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Paulette Anderson Psychiatry median Middle half National median
2019 $253 $184 $59–$605 $163
2020 $263 $119 $36–$372 $114
2021 $469 $143 $43–$576 $132
2022 $431 $153 $50–$590 $149
2023 $359 $170 $56–$651 $160
2024 $484 $179 $57–$673 $164
2025 $310 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $552 27 payments
  2. ITI, Inc. $365 20 payments
  3. Neurocrine Biosciences, Inc. $305 17 payments
  4. Otsuka America Pharmaceutical, Inc. $259 15 payments
  5. Alkermes, Inc. $187 8 payments
  6. Janssen Pharmaceuticals, Inc $169 10 payments
  7. Sunovion Pharmaceuticals Inc. $169 10 payments
  8. Teva Pharmaceuticals USA, Inc. $137 8 payments
  9. Allergan Inc. $121 8 payments
  10. Vanda Pharmaceuticals Inc. $102 5 payments
  11. Other $204 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,539 137 payments
  2. Education $30 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $514 25 payments
  2. CAPLYTA $288 17 payments
  3. INGREZZA $265 15 payments
  4. REXULTI $223 13 payments
  5. LYBALVI $187 8 payments
  6. INVEGA SUSTENNA $169 10 payments
  7. LATUDA $169 10 payments
  8. ARISTADA Cns $159 7 payments
  9. ARISTADA Cns $159 7 payments
  10. VRAYLAR Neuroscience $158 10 payments
  11. Other $1,062 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abiomed $38 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

604

Median for Psychiatry: 574

Drug cost

$13,800

Median for Psychiatry: $27,624

Branded share of claims

25.8%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Concerta Methylphenidate Hcl Brand 12 $4,743
Lurasidone Hcl Generic 11 $3,659
Quetiapine Fumarate Generic 112 $1,109
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 25 $889
Hydroxyzine Hcl Generic 20 $562
Divalproex Sodium Er Divalproex Sodium Brand 12 $310
Olanzapine Generic 29 $274
Buspirone Hcl Generic 31 $270
Aripiprazole Generic 27 $230
Bupropion Xl Bupropion Hcl Brand 39 $224

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$19,502

Medicare's payments for the services billed

Medicare patients

32

Average age 60

Services billed

197

21 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Depression 50%
Arthritis 38%
Diabetes 34%
Ischemic heart disease 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $207
$207 — —
VRAYLAR
  • AbbVie, Inc. $81
$81 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $68
$68 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $45
$45 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

139 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record